Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
NCT ID: NCT05127096
Last Updated: 2021-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2020-12-15
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
Cohort A will include subjects with a recent diagnosis of colorectal cancer and/or advanced adenoma requiring additional endoscopic or surgical resection (surgery).
FirstSight blood test
FirstSight blood test for colorectal cancer screening
Cohort B
Cohort B will include subjects undergoing routine screening colonoscopies will be enrolled in the screening cohort.
FirstSight blood test
FirstSight blood test for colorectal cancer screening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FirstSight blood test
FirstSight blood test for colorectal cancer screening
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be 45-80 years of age (inclusive) at the time of screening.
* Be recently diagnosed with primary colorectal cancer or advanced adenoma with plans to surgically remove the target lesion.
To enroll in Cohort B, a subject must:
* Be 45-80 years of age (inclusive) at the time of screening.
* Be planning to undergo a screening colonoscopy within 30 days after providing signed informed consent.
Exclusion Criteria
* Inflammatory bowel disease (IBD)
* Personal or family history of colorectal cancer syndromes or other hereditary cancer syndromes
To enroll in Cohort B, a subject must NOT have:
* Personal history of colorectal cancer, colorectal adenoma or aerodigestive tract cancer.
* Personal or family history of Familial adenomatous polyposis (FAP).
* Personal or family history of Hereditary non-polyposis colorectal cancer syndrome (HNPCC or Lynch Syndrome).
* Positive fecal occult blood testing (FOBT) within the previous 6 months.
* Positive fecal immunochemical testing (FIT) in the previous 6 months.
* Colorectal resection for any reason other than sigmoid diverticular disease.
* Overt rectal bleeding within the previous 30 days.
* Personal history of any cancer diagnosed \<5 years prior.
* Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and Crohn's disease.
* Colonoscopy within the previous 9 years.
* Barium enema, computed tomographic colonography, or sigmoidoscopy within the previous 5 years.
* ≥ 2 first-degree relatives who have been diagnosed with colorectal cancer (Note: First degree relatives include parents, siblings and offspring).
* 1 first-degree relative with CRC diagnosed before the age of 60.
* Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 30 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy.
* Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
45 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CellMax Life
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rui Mei, PhD
Role: STUDY_DIRECTOR
CellMax Life
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CellMax Site A
Huntsville, Alabama, United States
CellMax Site O
Chula Vista, California, United States
CellMax Site L
Lancaster, California, United States
CellMax Site J
Tustin, California, United States
CellMax Site P
Coral Gables, Florida, United States
CellMax Site D
Coral Springs, Florida, United States
CellMax Site G
Coral Springs, Florida, United States
CellMax Site C
Miami, Florida, United States
CellMax Site B
Metairie, Louisiana, United States
CellMax Site N
Mentor, Ohio, United States
CellMax Site M
Camp Hill, Pennsylvania, United States
CellMax Site K
Houston, Texas, United States
CellMax Site E
McAllen, Texas, United States
CellMax Site F
Pasadena, Texas, United States
CellMax Site H
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO00100
Identifier Type: -
Identifier Source: org_study_id